ClinicalTrials.gg
CompletedNCT00820417Updated Jan 12, 2009

Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib

A Phase 1 interventional study of Cetuximab/Gefitinib combination and/or monotherapy in Colorectal Cancer, Head and Neck Cancer and Non Small Cell Lung Cancer (NSCLC), sponsored by Harrison Clinical Research. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-01-12.

Sponsored by Harrison Clinical Research · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Enrollment
91st of 185
63 · median 60
Started
2004
with 9 others
Phase 1
19 of 187
3 open now
Registered
72nd of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 91st largest by enrollment of the 185 interventional ones that give a count, is one of 10 that started in 2004, is one of 19 in phase 1, and was the 72nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR. Primary objective is the determination of the maximum tolerated dose (MTD) and recommended dose (RD) of the combination of intravenous Cetuximab and oral Gefitinib.

Read the detailed description

Between 36 and 66 patients will be enrolled depending on the number of dose levels which can be completed. Patients will have histologically confirmed EFGR-expressing solid malignant tumours (colorectal cancer, head and neck cancer and NSCLC), which did not respond to standard therapy or for which no suitable therapy exists.

03

Conditions studied

  • Colorectal Cancer
  • Head and Neck Cancer
  • Non Small Cell Lung Cancer (NSCLC)

Keywords

  • cetuximab
  • monoclonal
  • antibody
  • epidermal
  • growth
  • factor
  • receptor
  • EGFR
  • Gefitinib
  • tyrosine
  • kinase
  • inhibitor
  • advanced
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written prior to inclusion
  • Confirmed histological diagnosis of non-resectable, solid, malignant, EGFR expressing tumours of the following types: colorectal cancer, head and neck cancer and non-small cell lung cancer (NSCLC). Advanced clinical stage III/IV which did not respond to standard therapy or for which no suitable therapy exists
  • Patients with at least one evaluable lesion (evaluable disease) by the criteria
  • Availability of tumour tissue, whether from primary tumour or to determine EGFR expression
  • Viability of establishing outpatient treatment
  • Effective for patients of both sexes if there is a risk of conception
  • performance status greater than 70 %
  • > 12 weeks
  • Adequate renal function (creatinine \< 1.5 x UNL), liver function ( \< 1.5 x UNL, /AST \< 2.5 x UNL o \<5 x UNL if hepatic metastasis) and adequate bone marrow (leucocytes > 3000/µl, > 1500/µl, > 100,000/µl, > 9 g/dl)
  • Patients must not have undergone chemotherapy, radiotherapy or major surgery during the 3 weeks before the beginning of the study, and they must have recovered from the relevant secondary effects of previous treatments
  • Patients agree to have a new after two weeks.

Exclusion criteria

Exclusion Criteria:

  • Patients with any symptom of bowel obstruction and/or inflammatory bowel disease
  • Previous therapy with anti-EGFR drugs
  • Patients with known cerebral
  • Patients with known active and uncontrolled infections
  • Severe uncontrolled organic dysfunctions or metabolic disorders
  • Patients unable to give
  • Patients who do not wish to or who cannot undergo the specific study treatments and the study procedures
  • Pregnancy or breastfeeding
  • Patient participation in another clinical trial during the previous 30 days
  • Patients with known drug and/or alcohol abuse
  • Known to chimeric MoAbs or pretreatment with MoAbs
  • Any other malignant tumour in the last two years or previously diagnosed malignant tumour if there is no guarantee that it is under complete control, except for suitably treated in situ cervical carcinoma or basocellular carcinoma
  • Known severe hypersensitivity to ZD1839 or any of the of this product
  • Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not to be excluded)
  • Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2 from previous anticancer therapy
  • Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    a

    Dose-escalation

    Drug: Cetuximab/Gefitinib combination and/or monotherapy

  • Experimental
    B

    Maximum tolerated dose (MTD)

    Drug: Cetuximab/Gefitinib combination and/or monotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of the combination intravenous Cetuximab/oral Gefitinib.

Secondary outcomes

  1. To determine the pharmacokinetic (PK) parameters of the combination Cetuximab/Gefitinib

  2. To determine the pharmacogenomic profile of study patients and to correlate the different profiles with efficacy

  3. To determine the possible correlation between activity and the polymorphisms of the EGFR measured in the blood and in the primary tumour

  4. To assess the possible immune response related to cetuximab

  5. To estimate signs of clinical activity (response rate according to the RECIST criteria)

07

Study locations

2 sites
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Sep 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2009
First posted
Jan 12, 2009
Start
Jun 2004
Primary completionActual
Sep 2007
CompletionActual
May 2008
Last update
Jan 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00820417
Lead sponsor
Harrison Clinical Research
First posted
Jan 12, 2009
Start date
Jun 2004
Primary completion
Sep 2007
Completion
May 2008
Last update
Jan 12, 2009

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Gefitinib

Start the discussion